Idiopathic Granulomatous Mastitis Clinical Trial
Official title:
A Prospective Open-label Single-arm Clinical Study of the Efficacy of Baricitinib for Idiopathic Granulomatous Mastitis in a Single Institution
This study will explore the mechanism of targeted drug in treatment of idiopathic granulomatous mastitis, and clarify the clinical classification and corresponding markers.
This study is aim to explore the mechanism of baricitinib in regulating the occurrence and development of idiopathic granulomatous mastitis, as well as the clinical classification and potential markers of idiopathic granulomatous mastitis. The target population of interest in this study is patients with non-lactating mastitis, which requires core needle biopsy pathology to indicate mastitis or biopsy pathology of palpable mass indicates chronic interstitial cell infiltration. Measurable lesions are required. The primary end point was the clinical complete remission rate, and the secondary end point was the degree of focus reduction, the recurrence rate within 12 months after drug withdrawal, the degree of inflammation markers decline, and the toxicity and side effects of the drug. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Not yet recruiting |
NCT04424615 -
Idiopathic Granulomatous Mastitis
|
||
| Active, not recruiting |
NCT04096300 -
An Integrative Approach for Idiopathic Granulomatous Mastitis.
|
||
| Completed |
NCT05409586 -
Risk Factors and the Role of Albumin-to-globulin Ratio in Idiopathic Granulomatous Mastitis
|
||
| Recruiting |
NCT05361629 -
Idiopathic Granulomatous Mastitis Combination Therapy
|
N/A |